What Does Weed Do to Your Brain? How THC and Cannabis Affect the Brain

THC changes signalling through a system that the body already uses to regulate communication between cells. Its effects depend on the dose, route, timing, and person, rather than one uniform change across the brain.

The YouTube player loads only when you press Play. Playing connects to YouTube, which may use cookies and storage. See Privacy.

What THC does to the brain

THC means delta-9-tetrahydrocannabinol, the main intoxicating cannabinoid in cannabis. A cannabinoid is a chemical that interacts with cannabinoid signalling. Intoxication means a temporary change in mental or physical function after a substance enters the body.

The brain produces its own signalling molecules, including anandamide and 2-AG. These are endocannabinoids: cannabinoids that the body makes. They are chemically different from THC, so the brain does not make its own THC.

THC can act on some of the same receptors. A receptor is a cell protein that responds to a signal. Understanding these receptors helps explain changes in memory, movement, reward, and hunger.

This explanation follows the video from the plant to a synapse, then through the effects and risks. It also separates intoxication from drug-test detection. Those two processes follow different time courses.

The plant, its history, and heat

Female cannabis flowers have small resin-producing glands called trichomes. Cannabis contains more than a hundred identified cannabinoids. THC and cannabidiol, or CBD, are two well-known examples.

THC produces the characteristic intoxication. CBD does not produce the same THC-like intoxication. That difference does not make every CBD product effective, harmless, or identical to a tested medicine.

Evidence of cannabis burning reaches back about 2,500 years at Jirzankal Cemetery in the Pamir Mountains of western China. Researchers identified chemical residues in wooden burners. The results suggest use of plants with relatively high intoxicating potential.

The residues do not establish exactly how people selected those plants. Cultivation and collection of naturally stronger plants remain different possible explanations. The archaeological evidence does not identify a modern product or dose.

Much of the relevant material in a fresh plant is THCA, tetrahydrocannabinolic acid. It has an extra carboxyl group compared with THC. Heating can remove this group as carbon dioxide through a reaction called decarboxylation.

This chemical change helps explain why heating changes the material's effects. THCA does not produce THC-like intoxication in the same way. The distinction concerns chemical form, rather than a claim that raw plant material has no biological effects.

The endocannabinoid system and CB1

Yechiel Gaoni and Raphael Mechoulam identified THC's structure in 1964. Researchers later established cannabinoid binding sites in the brain. The 1990 milestone concerns cloning the CB1 receptor, not the first evidence of cannabinoid binding.

CB1 receptors occur widely in the nervous system. CB2 receptors have important roles in immune cells, although their distribution is not exclusive to those cells. The receptor names distinguish related proteins with different roles and patterns.

These discoveries raised a question: which natural body signals use these receptors? Researchers identified anandamide in 1992. Its name derives from the Sanskrit word ananda, meaning bliss.

Researchers identified 2-AG, or 2-arachidonoylglycerol, as an endocannabinoid in 1995. Anandamide and 2-AG differ in their chemistry and metabolism. The endocannabinoid system helps regulate pain, appetite, stress, and memory.

How signalling changes at a synapse

A synapse is a junction where a neuron communicates with another cell. A neuron is a nerve cell. At a chemical synapse, the sending neuron releases a messenger that acts on the receiving cell.

Endocannabinoids can provide a signal in the reverse direction. The receiving cell produces them in response to activity. They act on CB1 receptors at the sending side and can reduce further messenger release.

Scientists call this retrograde signalling. The word retrograde describes the reverse direction relative to the usual chemical message. The video's dimmer-switch picture represents this feedback control.

The sequence is:

1. The sending cell releases a chemical messenger.
2. Activity in the receiving cell stimulates endocannabinoid production.
3. Endocannabinoids act on CB1 receptors at the sending side.
4. CB1 signalling reduces release of the relevant messenger.

The enzyme FAAH helps break down anandamide. An enzyme is a protein that speeds a chemical reaction. This process helps keep the natural signal local and brief.

THC does not depend on the receiving cell making an on-demand signal. It arrives through the blood and can act for much longer. FAAH does not clear THC through the same process that clears anandamide.

However, THC does not reach every CB1 synapse at the same instant or produce the same effect everywhere. CB1 can reduce excitatory or inhibitory transmission. Excitatory signals promote activity; inhibitory signals restrain it.

Reducing an inhibitory signal can increase activity farther along a circuit. The net effect therefore depends on the circuit. A single dimmer that turns down the whole brain is an incomplete model.

Where THC acts

CB1 receptors are abundant in several brain regions. These include the hippocampus, cerebellum, basal ganglia, and cerebral cortex. Their distribution helps explain the range of effects without predicting every person's experience.

The hippocampus supports learning and memory. The cerebellum and basal ganglia help control movement and timing. The cortex supports many functions, including perception, planning, and decision-making.

These regions communicate with each other. A change in one receptor system can affect several connected functions. A labelled brain diagram should therefore show a guide to functions, not isolated boxes with single jobs.

Memory and the sense of time

Acute THC exposure can impair learning and short-term memory. Someone may lose track of information while trying to use it. This differs from proving permanent loss of stored memories or death of brain cells.

THC can also alter estimates of elapsed time. In laboratory tasks, participants can judge that more time has passed than actually has. The effect depends on the task, dose, and study conditions.

A rat experiment helps explain one possible mechanism. A cannabinoid drug disrupted the timing of activity across hippocampal neurons. The rats also performed worse on a memory task.

The video compares coordinated activity with musicians keeping time. Individual neurons can still fire while their timing becomes less coordinated. The experiment supports a possible mechanism; it does not establish the complete explanation of human memory impairment.

Coordination, driving, and blood tests

THC can impair reaction time and coordination. Controlled driving studies find increased variation in a vehicle's position within a lane under relevant conditions. This provides a measurable example of impaired control.

One reanalysis of crash studies originally reported odds ratios of 1.22 and 1.36. A later correction changed these estimates to 1.18 and 1.32. These correspond to about 18–32% higher odds under its different statistical methods. Odds and probability are different quantities, so this is not an exact personal risk increase.

The video contrasts this with an alcohol crash estimate near fourfold. The cited NHTSA study uses breath alcohol of 0.08 grams per 210 litres. Its adjusted crash-risk estimate is about 3.9 times the risk with no alcohol.

These numbers come from different analyses and do not form a controlled comparison between equal doses. Breath alcohol and blood THC also use different tests and concentration units.

Neither comparison makes cannabis-impaired driving safe. It also does not establish one legal alcohol limit for every place. The scientific issue here concerns changes in driving performance.

THC concentration in blood is an imperfect measure of current impairment. Concentration changes rapidly after use, and regular users can retain detectable THC later. A detected amount and a person's ability to drive are not interchangeable measurements.

Dopamine and reward

Dopamine is a chemical messenger involved in reward, motivation, and movement. Some animal experiments show that cannabinoid signalling reduces inhibitory input to dopamine neurons. Those neurons can then become more active.

This is disinhibition: reducing a brake increases the activity that the brake normally restrains. It explains why reducing messenger release at one synapse can increase output elsewhere.

Human brain-imaging studies show smaller and less consistent dopamine effects than a simple animal model might suggest. Dopamine therefore does not provide the whole explanation for cannabis intoxication. Species, experimental methods, and brain circuits matter.

Anxiety and paranoia

THC can produce different effects on anxiety. In a controlled study of 42 healthy volunteers, the lower tested dose reduced distress after a stressful task. The higher tested dose increased negative mood and anxiety-related responses.

This result does not establish a treatment dose for a reader. It shows that a larger dose can change the direction of an effect. Panic, paranoia, and distress remain possible adverse effects.

The setting and the person's previous experience also affect the response. A result from a controlled experiment does not guarantee the same experience elsewhere.

Why appetite changes

The video presents two mouse studies. In one, cannabinoid signalling changed the feeding-related output of hypothalamic POMC neurons. The hypothalamus is a brain region involved in functions such as appetite regulation.

POMC neurons normally contribute to signals associated with reduced feeding. Under the study's cannabinoid conditions, their activity instead helped promote feeding. The result concerns the circuit's output, not a literal fullness switch that behaves identically in everyone.

Another mouse study links CB1 signalling in olfactory circuits with food detection and feeding. Olfactory means related to smell. Changes in this circuit helped mice detect food odours under the tested conditions.

Together, the studies provide mechanisms through which cannabinoid signalling can influence appetite. They do not prove that every human appetite change follows only these two routes.

Heart rate, red eyes, and dry mouth

THC can increase heart rate. An NIDA research report describes increases of about 20–50 beats per minute after smoking. This is a reported range, not a prediction for every exposure or person.

Blood vessels at the eye's surface can widen and make the eyes appear red. This local effect does not require a simple explanation through reduced blood pressure throughout the body. The eye's response and systemic blood pressure need separate descriptions.

Cannabinoid effects on salivary function can reduce saliva and cause dry mouth. These body effects show why the receptor system matters outside memory and mood alone.

Smoking, vaping, and edibles

Inhaled THC passes from the lungs into the blood and reaches the brain rapidly. Blood concentrations rise within minutes. Prominent effects often decline over about 1–3 hours, although impairment or other effects can last longer.

An edible must pass through digestion and absorption. Effects can start about 30 minutes to 2 hours later. The delay varies with the product, dose, food, and person.

The liver converts THC into metabolites, including active 11-hydroxy-THC. A metabolite is a product of the body's chemical processing. Oral exposure generally produces more of this active metabolite relative to THC than inhalation does.

The narration describes 11-hydroxy-THC as equally strong. A single strength ratio is too simple because experimental endpoints and species differ. The important point is that this metabolite remains pharmacologically active.

Edible effects can peak around 2–3 hours and last 6 hours or longer. These are broad time ranges, not a timetable that guarantees recovery. Different products and people can have substantially different responses.

The delay creates a common poisoning problem. A person may take more before the first amount produces its full effect. The combined exposure can then produce unexpectedly severe symptoms.

Detection and tolerance

THC dissolves in fat and can remain in body tissues. Slow release and later metabolism help explain prolonged detection after repeated use. Urine tests usually detect metabolites, rather than directly measuring present intoxication.

An older study of chronic users found positive results for up to 46 consecutive days under monitored conditions. That study used a sensitive cutoff of 20 nanograms per millilitre. A nanogram is one billionth of a gram.

The result does not mean everyone tests positive for that long. It also does not mean those participants remained intoxicated throughout the detection period. Test method, cutoff, and pattern of use matter.

Repeated exposure can produce tolerance, meaning a smaller response to a similar dose. PET imaging studies report roughly 15–20% lower CB1 receptor availability in relevant comparisons involving frequent users. Availability is an imaging measure, not a direct count of every receptor on every cell.

Studies show recovery of receptor availability during abstinence, with substantial changes over about four weeks. Some changes begin earlier. This does not prove that every effect of long-term use disappears on the same schedule.

Potency and CBD

Historical US seizure data show mean THC content rising from about 4% in 1995 to about 16% in 2022. The rounded comparison is a fourfold increase. These are police-seized samples, not a measurement of every product or every market.

That historical comparison uses the ratio of mean THC concentration to mean CBD concentration. The ratio rose from about 14:1 to about 135:1. This means much less CBD relative to THC. This calculation divides two sample averages; it does not average the ratio within each individual sample.

Separate research on modern regulated retail products also reports high THC concentrations. It is a different dataset and cannot simply replace the historical seizure series. Individual products vary widely in THC, CBD, and route of use.

CBD interacts with the cannabinoid system differently from THC. A controlled trial of tested CBD-to-THC ratios did not show reliable protection against THC's acute adverse effects. CBD therefore does not automatically cancel impairment or distress.

The claim that all present-day cannabis contains almost no CBD is too broad. The evidence concerns particular samples and products. Product composition requires its own measurement.

Addiction and other longer-term risks

The often-repeated three-in-ten figure needs a date and definition. In a US survey from 2012–2013, about 30.6% of past-year users met DSM-IV cannabis abuse or dependence criteria. DSM-IV names the diagnostic manual used for that analysis.

This is a proportion within a surveyed group, not the chance that every new user will later develop a disorder. The study did not use DSM-5 severity categories. Starting young and using frequently remain important risk factors.

Withdrawal can follow reduced use or cessation after frequent exposure. Symptoms include irritability, disturbed sleep, reduced appetite, and unusual or vivid dreams. Symptoms often peak during the first week and decrease over the following weeks.

Some symptoms, especially sleep problems, can persist longer. A typical pattern is not a fixed deadline for every person. Withdrawal and craving also differ from the duration of an acute intoxicating effect.

Brain development continues into the twenties. Age 25 is a broad teaching approximation, not a switch that completes every person's development. Exposure during adolescence therefore raises concerns distinct from exposure later in adulthood.

A New Zealand study associated persistent use beginning in adolescence with cognitive decline, including several IQ points by midlife. Twin studies show that shared family and other differences can explain part of such associations. These results support caution without proving a universal causal IQ loss.

Adult structural brain studies also give mixed results. One study with careful alcohol matching found no relevant group differences in its selected measures. A larger review reported small average differences in areas such as the hippocampus and orbitofrontal cortex.

The orbitofrontal cortex contributes to evaluation and decision-making. A difference in an MRI measurement does not directly show dead brain cells. Observational scans alone also cannot establish whether cannabis caused a difference.

The EU-GEI study compared 901 people with first-episode psychosis against 1,237 population controls. Daily cannabis use had an adjusted odds ratio of 3.2 compared with never-use. Daily high-potency use had an adjusted odds ratio of 4.8.

Those figures explain the video's rounded threefold and fivefold comparisons. They describe odds in an observational study, not certainty or proof of cause. Psychosis involves problems such as losing contact with reality through hallucinations or delusions.

Some people with long-term heavy use develop cannabinoid hyperemesis syndrome. This condition involves repeated severe nausea and vomiting. Hot showers can provide temporary relief for some patients, but they are not a cure.

Stopping cannabis is central to lasting resolution in the reported cases. Severe vomiting still needs medical assessment because other illnesses can cause it. Resolution is not necessarily immediate.

Smoke adds risks separate from THC's receptor effects. Regular cannabis smoking has links with chronic cough and bronchitis symptoms. Bronchitis involves inflammation of the airways.

Evidence also links cannabis smoking during pregnancy with lower birth weight. This association does not isolate every possible contribution from tobacco or other exposures. It does not establish that another route is safe during pregnancy.

Overdose and poisoning

A fatal overdose from cannabis alone is unlikely, but cannabis poisoning can still cause serious symptoms. Edibles create particular problems through delayed effects and accidental ingestion. Children can become ill after eating products that resemble ordinary food.

Opioids can directly suppress breathing through their receptor effects. Low CB1 density in important breathing-control regions is one proposed explanation for cannabis's different toxicity pattern. It is not proof that cannabis cannot harm breathing or cause a medical emergency.

Emergency visits and nonfatal poisoning remain real outcomes. Unlikely fatal overdose and absence of risk are different statements.

Medical uses

Some cannabinoid medicines have evidence and regulatory approval for specific conditions. FDA approved dronabinol capsules in 1985 for certain chemotherapy-related nausea and vomiting. Dronabinol is a pharmaceutical form of THC.

FDA first approved the CBD medicine Epidiolex in 2018 for seizures associated with Lennox–Gastaut and Dravet syndromes. These are specific epilepsy conditions. Approval of that tested medicine does not establish equal effectiveness for ordinary retail CBD products.

Reviews also find evidence of benefit for some adults with chronic pain, with generally modest average effects. The result depends on the medicine and condition. It does not mean CBD alone treats every kind of pain.

A medical decision requires discussion of the condition, evidence, adverse effects, and other medicines with a qualified clinician. The mechanisms in this article do not select a treatment for an individual reader.

What this means

The body's cannabinoid system helps control communication between cells. THC changes that control with a different timing and distribution from the body's own signals. The resulting effects vary across memory, movement, mood, appetite, and other functions.

The dimmer-switch analogy is useful at a specific synapse. It becomes misleading when it implies uniform suppression of the whole brain. Route, dose, product strength, frequency, and individual differences all affect the outcome.

FAQ

Does the brain make THC?

No. It makes endocannabinoids such as anandamide and 2-AG. These can act on some of the same receptors as THC.

Does a positive urine test prove current impairment?

No. Detection of metabolites can continue after acute intoxication ends. A test result requires its own timing and method context.

Does CBD reliably prevent THC impairment?

No. The cited controlled trial does not support that general claim.

Does three in ten mean a lifetime risk for every user?

No. The cited number describes DSM-IV abuse or dependence among past-year users in a particular 2012–2013 survey.